AlphAIAlphAI — Financial news for AI agents
investing.comOCT 291 min read$TAK

Takeda Pharma ADR earnings beat by $1.81, revenue topped estimates

Takeda Pharma ADR (TAK) reported Q3 EPS of $1.96, exceeding estimates by $1.81, with revenue at $15.29B, above consensus. The company provided FY 2026 guidance of $482 EPS and $4.7T revenue. TAK's stock is up 17.91% in 3 months and 52.31% in 12 months.

Original reporting
investing.com
Published Oct 29, 2026, 8:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TAK
Bullish
high confidence
Mentioned
$TAK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TAKBullishHigh
01

Why it matters

The earnings surprise and guidance are likely to drive short-term buying interest.

02

Market read

Strong earnings beat and guidance provide a fresh catalyst for TAK, with potential spillover to the pharma sector.

03

What to watch

Potential regulatory or pipeline risks not addressed in the brief earnings release.

Relevance 8/10Novelty 9/10Timing: today

Background

Takeda Pharma ADR (NYSE:TAK) announced its Q3 earnings and FY2026 guidance.

Company-level read

Ticker impact

$TAKBullishHigh confidence
Context

Takeda Pharma ADR reported Q3 EPS of $1.96, beating estimates by $1.81 and revenue of $15.29B versus $7.32B consensus, plus FY2026 guidance of $482 EPS and $4.7T revenue.

Expected impact

upward pressure as investors price in the earnings beat and robust FY guidance

Evidence & confidence

The surprise magnitude of both EPS and revenue, combined with bullish FY guidance, provides a clear catalyst for price appreciation.

Market effects

Sector

Positive earnings may boost sentiment in the pharmaceutical sector.

Regional

May support broader Asian pharma stocks.

Global

Limited to pharma investors; no broad market effect.

Counterpoint

What could challenge this read

If the guidance proves overly optimistic, the stock could face disappointment on future results.

Key entities

  • company
    Takeda Pharma ADR

    Japanese pharmaceutical company listed on NYSE via ADR.

Read at source← All news

Related articles

OCT 31
$TAKMed

Key facts: TSE:4502 keeps guidance; launches ORZEYFUL; 3k roles cut

Takeda (4502) maintained full-year guidance, expecting a low-single-digit revenue decline at constant FX. The company raised revenue and core operating profit forecasts, launched ORZEYFUL for narcolepsy, and plans a U.S. launch. Takeda cut 3,000 roles, achieved procurement savings, and aims for ¥100B gross savings by FY2026. The FDA approved MIMRYLO for erythrocytosis, and accepted zasocitinib for priority review. ENTYVIO showed reduced UC complications in a study.

tradingview.com1 min
OCT 30
$TAKMedAI 8/10

What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

Takeda Pharmaceutical (TAK) reported on its Q2 earnings call, highlighting launches of ORZEYFUL for narcolepsy in Japan and China, with a U.S. launch expected in November. MIMRYLO for polycythemia vera received FDA approval and is commercially available. The company also announced positive phase III data for TAK-921 in gastric cancer. Takeda maintained its full-year revenue outlook but raised core operating profit guidance to ¥1.19 trillion, citing foreign-exchange assumptions.

finance.yahoo.com3 min
OCT 29
$TAKMed

Takeda (TAK) Q2 2026 Earnings Call Transcript

Takeda (TAK) reported Q2 2026 earnings, highlighting successful product launches like ORZEYFUL and MIMRYLO, and progress in its pipeline. ORZEYFUL, a narcolepsy treatment, launched in Japan and China, with a U.S. launch expected in November. MIMRYLO, a polycythemia vera treatment, launched in the U.S. in August. The company also secured regulatory submissions for zasocitinib in psoriasis and TAK-881 for primary immunodeficiency.

finance.yahoo.com3 min
OCT 29
$TAKHighAI 8/10

Takeda FY2026 Q2 slides: new medicines set growth trajectory

Takeda Pharmaceutical (NYSE:TAK) reported FY2026 Q2 earnings, with core revenue at JPY 2,407.0 billion ($15.3 billion) and core operating profit at JPY 710.6 billion ($4.5 billion). The company highlighted growth from three new medicines: ORZEYFUL, MIMRYLO, and zasocitinib. Operating cash flow decreased 27.2% to JPY 431.9 billion, and free cash flow fell 38.0% to JPY 325.7 billion. Takeda maintained its annual dividend of 204 yen per share.

investing.com3 min
OCT 29
HighAI 8/10

TAKEDA PHARMACEUTICAL CO LTD (TAK): Financial results for H2 2026

TAKEDA PHARMACEUTICAL CO LTD (TAK) furnished an SEC Form 6-K — earnings release. Information furnished on this form: EXHIBIT Exhibit Number 1. (English Translation) Earnings Report (Kessan Tanshin) for the Six -month Period Ended September 30, 2026 99.1 Financial Appendix SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the regi

SEC EDGAR 6-K2 min